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Abstract: As the scope of nanotechnology applications in medicine evolves, it is important to 
simultaneously recognize and advance contributions germane to public health. A wide range of 
innovations in nanomedicine stand to impact nearly every medical specialty and unveil novel ways 
to improve the quality and extend the duration of life – these gains can be measured at both indi-
vidual and population levels. For example, heart disease and cancer combined make up approxi-
mately half of all deaths in the United States per year, and already, advances in   nanomedicine 
demonstrate great potential to reduce rates of morbidity and mortality due to these diseases. 
Meanwhile, public health applications of nanomedicine such as rapid and portable diagnostics 
and more effective vaccinations have the potential to revolutionize global health. Research driven 
by innovators across disciplines such as engineering, biology, medicine, and public health should 
collaborate in order to achieve maximal potential impact in health for individuals and popula-
tions. In turn, knowledge gaps regarding the potential health and safety implications of exposure 
to engineered nanomaterials must be continuously addressed and actively researched. Dynamic, 
proactive, and socially responsible research will drive   nanomedicine as it plays an increasingly 
integral and transformative role in medicine and public health in the 21st century.
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Introduction
Applications of nanotechnology in the screening, diagnosis, and treatment of   disease 
are collectively referred to as “nanomedicine” – an emerging field that has the 
potential to revolutionize individual and population-based health in the 21st century. 
While clinical medicine targets health at the individual level, the mission of public 
health is to promote, protect, and preserve health for groups of people or populations.1 
To maximize the benefits and minimize potential harms for the greatest number of 
people, it is essential to investigate and explore the potential applications and impacts 
of nanomedicine through the lens of public health.
The attractiveness of nanotechnology applications lies in the unique characteristics 
and phenomena that manifest due to their small size. The most widely accepted definition 
of scale for nanotechnology is 1–100 nm.2 Engineering materials on this scale allows for 
novel medical therapies such as designing nanoparticle-based drugs that target cells with 
improved specificity, resulting in decreased side effects for patients.3 Other advances are 
being made in medical devices and instrumentation for use in surgical procedures that 
are less invasive, leading to shorter recovery times and decreased risk of postoperative 
infections or other complications. Such innovations will improve the quality of life, 
extend life expectancies, and could reduce the overall cost of healthcare.International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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Research is currently underway on a global scale to 
develop nanotechnology applications in cardiology, neurology, 
and many other medical specialties. These applications range 
from nanoparticles in targeted drug delivery systems to carbon 
nanotubes for enhancing the diagnostic   capacity of imaging 
modalities.4 Research driven by scientists with a keen eye on 
the needs of public health is essential in   successfully advancing 
the field and developing medical technologies for practical 
use. At the same time, knowledge gaps regarding the fate and 
transport of engineered nanoparticles in biological systems 
need to be continuously addressed.5 In the United States, there 
are no specific regulations set forth by the United States Food 
and Drug Administration (FDA) for engineered nanomaterials 
in consumer products under their jurisdiction. However, there 
is growing concern about possible health and safety risks 
and the lack of information available to predict and mitigate 
potential health effects associated with exposure to engineered 
nanomaterials. Additional research needs to be conducted to 
adequately assess the life-cycle of engineered nanomaterials 
and how this will impact environmental and human health and 
safety. Meanwhile, communication with stakeholders about 
potential risks and benefits is critical to responsibly advance 
nanotechnology.
Implementation of nanomedicine into routine clinical 
practice will face many challenges from regulatory agencies, 
concerned public groups, insurance companies, and others for 
a variety of reasons. Collaboration between those with a vested 
interest in advancing nanomedicine should be encouraged 
to address these challenges at an early stage. Public health 
professionals should play an integral role in shaping future 
nanomedicine research as well as clinical and population-
based implementation. Their responsibilities will range from 
collecting and analyzing epidemiologic data on the effective-
ness of nanoenabled drugs to advocating for increased funds to 
support research. With proper due diligence and collaboration, 
the fields of nanomedicine and public health will accelerate 
each other in a variety of ways to improve human health more 
efficiently than either could do individually.
The goal of this article is to educate stakeholders who 
include the general public, members of industry, government, 
and academia involved in advancing nanomedicine about 
public health concepts that should be proactively incorpo-
rated into the research, development, and implementation of 
this rapidly growing field.
Public health
Nanomedicine is poised to impact all aspects of public health. 
Public health is defined as “The science and art of preventing 
disease, prolonging life and promoting health and efficiency 
through organized community effort.” This often includes 
community-wide or population-based interventions such 
as public sanitation, infectious disease control, and clinical 
preventive services including early screening and detection. 
In this way, public health works to promote the health of each 
person in a community through organized efforts that impact 
groups of people as well as individuals.6 The field of public 
health is broken down into the following five core disciplines 
according to the Association of Schools of Public Health:7
•	 Epidemiology
•	 Biostatistics
•	 Health policy management
•	 Social and community behavior
•	 Environmental health sciences.
Epidemiology is the study of determinants and distribution 
of disease.2 It articulates with biostatistics, which quantita-
tively analyzes the determinants and distribution of disease. 
Health policy and management uses information from disci-
plines in medicine and public health to create laws, regula-
tions, and guidelines for the good of the public’s health. Social 
and community behavior studies individual through organi-
zational level impacts on health outcomes.7 Environmental 
health focuses on how the physical and social environment 
affects human health, as well as how humans are affecting 
their surrounding environment.8 The knowledge base achieved 
through these core disciplines provides a platform for public 
health professionals to analyze, understand, and predict the 
implications of nanomedicine on population health.
Technological advances in public health have shaped 
human history. For example, vaccines have been successful 
in eradicating and drastically reducing deadly infectious 
diseases across the globe. Side effects and health risks have 
also played a role in how vaccines have been developed and 
utilized. The hepatitis B vaccine is one example of how 
nanotechnology can be used to enhance current medical 
practice and make a significant impact on population health. 
Hepatitis B is an infectious disease that has affected about 
two billion people across the world. Currently there is a 
highly effective vaccine to prevent this disease; however, it 
must be administered over the course of three to four doses.9 
Noncompliance with the dosing schedule is a significant 
problem, particularly in third world countries, rendering 
the vaccine less effective or completely ineffective. Ongo-
ing research and development has led to breakthroughs 
that enable the vaccine to be administered in one dose with 
equal effectiveness. One group is specifically investigating 
the effectiveness of different PLGA microspheres to deliver International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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the hepatitis B   vaccine in one dose.10 This type of preventive 
care for hepatitis B makes it feasible to vaccinate a larger 
population against a significant public health threat – an 
infectious disease that leads to approximately 600,000 
deaths a year.9
In terms of fighting chronic disease, nanomedicine has 
the potential to dramatically impact health within the United 
States as well as across the world. In the United States, 
cancer is the number two cause of mortality; it is estimated 
that in 2009, there were approximately 1.48 million cancer 
cases.11 Traditional cancer treatments such as chemotherapy, 
surgery, and radiation therapy are taxing on patients because 
these interventions are largely nonspecific; they damage 
both cancerous and healthy cells.12 The National Cancer 
Institute (NCI), recognizing the tremendous potential of 
nanotechnology to enhance the diagnosis and treatment 
of cancer, developed the Alliance for Nanotechnology 
in Cancer in 2004.13 This alliance fosters research and 
development of nanotechnology-based solutions ranging 
from diagnosis to treatment of cancer that are more efficient 
and have fewer side effects. The NCI provides support for 
many drugs and therapies harnessing nanotechnology in 
various phases of testing, all the way up through clinical 
trials. Currently, there are multiple nanoenabled drugs that 
have been approved by the FDA for the treatment of cancer, 
such as Abraxane®, which is used to treat breast cancer, 
and Doxil® for ovarian cancer.14,15 Advances in regenerative 
medicine utilizing carbon nanotubes and nanofibers, 
nanopatterned extracellular matrices, and dendritic nano-
polymers are a few examples of new technologies that are 
being developed to impact other major causes of morbidity 
and mortality in the United States, including cancer, 
Alzheimer’s disease, and heart disease.16–19 Research efforts 
focused on these highly prevalent diseases demonstrate how 
nanomedicine can be used in a variety of ways to tackle 
large public health issues.
Epidemiology and biostatistics
Epidemiologic research is a powerful tool used to track health 
determinants and distribution of diseases in populations to 
manage health problems.2 Complementary to epidemiology is 
biostatistics, which is defined as the application of statistical 
methods to biological and medical problems.20 Research in 
these disciplines revealed correlations between exposures and 
health outcomes that have dramatically changed medicine 
and public health practices. Epidemiologic investigations 
range from environmental exposures that may result in a 
certain disease, or a new medical intervention that may 
reduce the incidence of a particular disease. In conjunction 
with biostatistics, epidemiologists will monitor the impact 
nanomedicine applications will have on particular health 
outcomes of interest as well as overall population health. 
This will include comprehensive post-market surveillance 
studies of nanoenabled drugs to monitor their safety as well 
as effectiveness.21
Monitoring advances in nanotechnology that have 
the potential to influence health determinants, goals, and 
outcomes through epidemiologic surveillance will allow 
researchers to quantify their impact on population health. It is 
important not only to investigate the question, “does the appli-
cation of this technology improve health outcomes?” but also 
the critical question, “for whom does this technology improve 
health outcomes?” In the era of personalized medicine, we 
must demonstrate and validate the use of nanotechnology for 
individuals and groups based on pertinent physical, medical, 
and biological characteristics. Advances in personalized 
medicine through lab-on-a chip nanoarray   technologies 
will assist in the quantification and   understanding of how 
health outcomes are being affected by nanomedicine 
applications.22,23 The data and trend   information generated 
by epidemiology will advance our understanding of the “big 
picture” impact of these   technologies and also serve to reveal 
how they are advancing the health of people both nationally 
and internationally.
As nanomedicine applications become more mainstream 
in clinical care, information regarding how they are impacting 
health outcomes will help insurance companies make 
decisions based on cost-benefit analyses between new and 
traditional medical interventions. This could potentially 
drive down healthcare expenditures. In turn, this surveillance 
data will highlight areas of medical research that are in 
need of nanotechnology applications. Communication with 
federal agencies as to where these gaps persist will ensure 
that   funding is being allocated to the areas with the greatest 
potential impact. Epidemiologic surveillance of where 
nanomedicine applications are primarily being used will 
demonstrate whether there is an equal distribution among 
various populations in different regions of the world. These 
considerations, as well as the public policy, societal, and 
ethical implications, are important elements in guiding future 
applications of nanotechnology in medicine and health.
Health policy management
The two major components regarding public health policy 
and management that will be affected by nanomedicine 
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The responsibility of the FDA is to protect the health of 
the public by ensuring that biological products, cosmetics, 
national food supplies, medical supplies, and drugs are safe.24 
Currently, the FDA has not developed specific regulations for 
products containing nanomaterials; however, many products 
containing engineered nanomaterials do fall under their 
jurisdiction. These range from sunscreens to prescription 
drugs, which are raising concern among the public and 
lawmakers.
In 2006, a legal petition was filed by the International 
Center for Technology Assessment and other concerned 
consumers groups against the FDA for a perceived “lack of 
initiative” in regulating nanomaterial-containing products 
under their jurisdiction.25 In response to the legal petition, the 
FDA created a “Nano Task Force”. The task force produced 
a document entitled Nanotechnology: A Report of the U.S. 
Food and Drug Administration Task Force detailing how the 
FDA is addressing products containing engineered nano-
sized particles.26 Ultimately, the document states that they 
do not have sufficient health and safety information to treat 
  nanosized particles differently from larger particles of the 
same material composition. In the above report, the FDA rec-
ommends that labeling of nanoparticle-containing products 
should be evaluated on a case-by-case basis. However, they 
do not believe that the current state of the science proves that 
nanosized particles are cause for safety concern, and there-
fore do not need to be specifically labeled as such.26 Despite 
concern from advocacy groups like the Consumers Union, 
there have been no changes to their method of review for 
products containing nanomaterials. Additional and appropri-
ate toxicological data must be generated to effectively inform 
the regulation of products entering the market. A balance 
between protecting consumers and fostering innovation is 
necessary to responsibly advance nanotechnology.
The challenge of regulating engineered nanomaterials is 
not limited to the FDA. Other United States federal agencies 
that are also under pressure to ensure the safe development of 
nanotechnology include the Environmental Protection Agency 
(EPA) and the Occupational Safety and Health Administra-
tion. One significant challenge these agencies face is the lack 
of standardization of nanomaterials. The diverse nature of 
nanomaterials does not lend itself well to the current nomen-
clature used for chemicals. Material safety datasheets, which 
play a critical role in worker safety, are one example of how 
a standardized naming system is used to communicate health 
and safety information. From a policy standpoint, it is critical 
to have a universal and consistent naming system to begin 
developing regulations pertaining to particular engineered 
nanomaterials. Another current challenge for these federal 
entities is that knowledge gaps exist regarding the potential 
environmental and human health effects related to exposure 
to engineered nanomaterials. Health and safety research is 
lagging behind the rapid development of new nanotechnology-
based products. Limited federal funding to agencies charged 
with this type of research, such as the National Institute for 
Occupational Safety and Health (NIOSH), FDA, and EPA, 
is contributing to this lag. In 2009, NIOSH received approxi-
mately 0.4% of the total National Nanotechnology Initiative’s 
(NNI’s) budget. Their 2011 funding request is about two and 
a half times the 2009 budget and would comprise almost 1% 
of the total 2011 NNI budget.27 Other regulatory agencies 
are also requesting increased funding; this federal financial 
support is critical to fill the health and safety knowledge gaps 
and inform policymakers.
Advances in nanomedicine will also affect healthcare 
delivery systems. Screening modalities with higher sen-
sitivity and specificity for disease detection could greatly 
improve prognoses and decrease healthcare costs. Initially, 
there could be resistance from insurance providers to pay for 
certain treatments using nanomedicine. New technologies 
are often more expensive than traditional medical interven-
tions, and coverage is often opposed even though the new 
methods may be more effective. This is a challenge that will 
be overcome with time and sufficient data to clearly demon-
strate the benefits of new nanomedicine applications in the 
prevention, diagnosis, and treatment of disease. Healthcare 
providers and delivery systems could face financial chal-
lenges as they will bear the initial burden of purchasing new 
equipment and dedicating their time to learn about advances 
in nanomedicine in order to incorporate them into clinical 
practice. These real as well as perceived barriers should be 
overcome through a collaborative effort from all involved 
stakeholders. Public health professionals will play a key role 
in working with researchers who develop the technology to 
transparently disseminate information regarding risks, costs, 
and benefits to those who will implement them.
Social and community behavior
Often individuals’ health decisions are influenced by their 
perception of risks and benefits despite factual information. 
The health belief model describes this theory, and more 
specifically, how the media plays a role in decision making.28 
With books like Engines of Creation by Eric Drexler and 
Prey by Michael Crichton proposing that nanorobots will 
eventually take over the world, nanotechnology has been 
given a negative spin in the eyes of some.29,30 Current   studies International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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suggest that there is skepticism among the public about the 
safety of nanotechnology.31 In particular, nanomedicine may 
fall under more scrutiny than nanotechnology in general 
because its applications often take the form of direct medical 
interventions. Over the course of history, there are examples 
of emerging technologies that have been greatly hindered 
or even failed due to negative public and social perception. 
For example, genetically modified foods are considered to be 
safe for consumption, but due to negative public perception, 
the industry was not able to survive.32,33 Noncompliance with 
vaccinations due to public fear of adverse health effects is 
another example of how perception can affect medical deci-
sion making as well as the health of entire populations.34 
Stakeholders in nanomedicine must be proactive with regard 
to clear, consistent, and transparent communication with the 
lay public and policymakers. Strategic risk communication 
with the public is essential, especially in light of pre-existing 
stigma and fear about nanotechnology.
Environmental health
Understanding the environmental and human health implica-
tions of engineered nanomaterials, products, and byproducts 
and the processes involved in making them are critical to 
proactively explore. Early stage research implies that certain 
nanoparticles may be more persistent in the environment than 
others, highlighting the need to collect more information 
regarding risk assessment and management.35 Environmental 
regulation of nanomaterials falls under the EPA’s Toxic Sub-
stance Control Act.36 While there are over 1000 nanoenabled 
consumer products already on the market, knowledge gaps 
exist regarding their fate and transport within humans, the 
environment, and ecosystems.37 For example, many topical 
creams such as sunscreens that are already on the market 
contain titanium dioxide nanoparticles.38 Sunscreen brands 
that contain nanoparticles include Burt’s Bees®, Banana 
Boat®, Coppertone®, and many others.39 These products 
are intended for direct application to the skin where some 
of the material will be absorbed through the epidermis and 
some will be washed or rubbed off and enter public waste-
water systems. Another particle of concern is nanosilver 
due to its inherent antimicrobial nature and potential to 
alter the wastewater treatment environment. Water treatment 
facilities have not been specifically designed for removal of 
nanoparticles.40 Analysis of the entire life-cycle of engineered 
nanomaterials, from their raw materials to disposal, is an 
important part of responsibly advancing nanotechnology 
from a health and safety perspective.41 As the number of 
nanomaterial-containing products on the market continues 
to rise, there is increased awareness and concern regarding 
their environmental impact.
Similarly, nanoparticles used for medical interventions 
will have multiple points of entry into the environment 
based on their particular application, function, and disposal. 
This may include excreted nanoenabled drug products into 
wastewater, disposal of novel imaging agents, and medical 
devices at their end of life in a landfill. Currently, the FDA 
and EPA provide guidelines for the public on how to dispose 
of unused medications, as certain drugs have the potential 
to alter the wastewater treatment system.42,43 Therefore, it is 
critical to understand how nanopharmaceuticals will affect 
water treatment as well. Continued research is necessary to 
understand the impact of nanomaterials on the environment 
throughout all stages of their life-cycle.
Training
Public health professionals, medical practitioners, and sci-
entific researchers involved with developing and deploying 
nanomedicine applications should be versed in the basic 
concepts and principles of public health as they relate to 
emerging technologies. This will drive research in a direc-
tion that will most efficiently impact population health and 
allow for effective communication and collaboration between 
stakeholders from industry, government, and academia. The 
cohort charged with advancing nanomedicine will comprise 
many different types of professionals, which will necessitate 
truly interdisciplinary collaboration.
To assist with the implementation of emerging nano-
medicine applications into healthcare systems, public 
health workers will need to be familiar with the concepts 
of nanotechnology. Public health professionals should be 
educated about the growing field of nanomedicine and its 
implications for population health. This can occur through 
multiple mechanisms such as increasing the literature base 
through publication of nanomedicine articles directed 
towards the public health audience, incorporating sessions 
into major conferences such as the American Public Health 
Association annual conference, and offering seminars and 
workshops solely dedicated to educating public health profes-
sionals about the advances in nanomedicine. Subsequently, 
those involved with strategic planning of the future of nano-
medicine within government, industry, and academia should 
understand its potential to impact public health.
Education for clinicians will also be essential to effectively 
deploy these nanoenabled medical technologies in clinical 
practice. Applications in certain medical specialties and sub-
specialties such as radiology, infectious disease, and oncology International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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are currently racing ahead from research and development to 
commercial availability. The need for additional training and 
education in these medical specialty areas is more urgently 
needed than for other fields at this time; however, it is likely 
that all medical specialties will be directly impacted in the 
coming years. Expertise for developing educational and train-
ing modules for medical providers will need to come from a 
group that can understand and synthesize information from 
basic research and clinical medicine.
Training and education amongst all groups will need to 
occur in a cyclic manner. Public health professionals must 
become educated about nanotechnology and its advances 
in medicine to, in turn, educate researchers and medical 
professionals about its national and international impact 
on population health. This will require the formation of 
partnerships across disciplines and sectors resulting in more 
efficient translation of technology to patient care, which 
will ultimately improve individual and population health 
outcomes.
In addition, a new generation of physician scientists who 
are literate in both nanotechnology and medicine will propel 
new nanomedicine innovations into practice. As the art and 
science of medicine evolves rapidly in the face of cutting-
edge technologies, a new generation of clinical researchers 
is needed to integrate and accelerate the potential impact of 
these advances on human health. This truly hybrid cohort 
will play an integral role in driving clinical translational 
nanomedicine research from bench top to bedside. According 
to the National Nanotechnology Initiative, a solid educational 
foundation, a skilled workforce, and a state-of-the-art research 
and development infrastructure are essential in this regard.44 
Nanoscale science, engineering, and technology programs 
and resources are required to produce a new generation of 
researchers and inventors working at the nanoscale. Specific 
efforts should include the development of educational 
modules that incorporate nanotechnology into curricula for 
many disciplines contributing to nanotechnology.44 Many 
national groups and strategic federal initiatives, including 
the National Cancer Institute Alliance for Nanotechnology, 
specifically call for training programs designed to produce the 
next generation of nanomedicine researchers and encourage 
young people to pursue cross-disciplinary careers in science, 
medicine, and engineering.45
Conclusion
The opportunities for nanomedicine to improve health are 
limitless. To maximize gains in individual and population 
health, inclusion of public health expertise is essential. 
This influence in the development of nanomedicine will 
help to identify the greatest areas of need for technological 
innovation, determine how to best allocate funding, and 
shape polices to protect humans and the environment.
An important part of advancing nanomedicine is 
expanding cross-disciplinary training for researchers, medi-
cal care providers, and public health professionals working 
in industry, government, and academia. Taking a collabora-
tive approach to nanomedicine research and education will 
advance the state of the science efficiently, resulting in a 
greater return on investment for public health. Research and 
development of novel nanomedicine applications integrated 
with public health principles will transform human health 
across the world.
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